Through this partnership, PRISM BioLab's proprietary small molecule peptide-mimetic PepMetics® technology will be integrated with Elix's AI drug discovery platform "Elix Discovery™." ...

PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, announced that it has entered into a ...

This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab's proprietary peptide mimetic technology for controlling protein-protein interactions with ...